The U.S. Centers for Disease Control and Prevention decided, opens new tab to hold off recommending the use of the vaccine, Arexvy, in adults under 60, despite the Food and Drug Administration ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 50 to 59 ...

Nov 6 (Reuters) - An initial 899,000 vaccine doses have been allocated for 9 countries across Africa that have been hit hard by the current mpox surge, the WHO and other health organisations said ...

Three more successful launches cited by Trinity were for RSV vaccines, each of which significantly exceeded expectations. Those shots were GSK’s Arexvy, Pfizer’s Abrysvo and Sanofi and ...

The Alberta government is permanently cutting off the flow of publicly funded vaccines to community medical clinics, save a select few, sparking yet another wave of concern from health-care providers.

The company is likely to have generated a major portion of its revenues from selling its COVID-19 vaccine. Our model estimate for the vaccine’s sales is pegged at $1.12 billion, implying a ...

Reuters is an international news organisation owned by Thomson Reuters GSK has received Canadian approval for Arexvy, its respiratory syncytial virus vaccine in adults between 50 and 59 ...

There’s still one more step before Moderna’s vaccine can take on Arexvy and Abrysvo in the market. It will need to get endorsement from the Centers for Disease Control and Prevention (CDC ...

The vaccine was previously approved in Canada for adults aged 60 and over. Credit: MargJohnsonVA/Shutterstock. GlaxoSmithKline (GSK) has received approval for its ...

Oct. 17, 2024 — With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is ...